Screener
Bicara Therapeutics BCAX Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount at other companies
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxReconciliationTaxCreditsResearch.
The source filing: Bicara Therapeutics’s 10-K, filed March 30, 2026.
- Filed
- Mar 30, 2026, 12:00 AM EDT
- Fiscal year
- FY2025
- Accession
- 0001628280-26-022010
| Line item | Rate | Tax |
|---|---|---|
| At U.S. federal statutory rate | 21.00% | (28,924) |
| State taxes, net of federal effect(1) | (0.12)% | 165 |
| Tax credits | ||
| Research and Development credit | 2.45% | (3,377) |
| Changes in valuation allowances | (22.86)% | 31,487 |
| Nontaxable or nondeductible items | ||
| Stock compensation | (0.52)% | 712 |
| Other Nontaxable or nondeductible items | (0.04)% | 59 |
Item 16. Form 10-K Summary
FAQ
- What is Bicara Therapeutics's effective income tax rate reconciliation, tax credit, research, amount?
- Bicara Therapeutics (BCAX) reported effective income tax rate reconciliation, tax credit, research, amount of $844.25K in Q4 2025.
- What does effective income tax rate reconciliation, tax credit, research, amount mean?
- This metric represents the absolute dollar value of research and development tax credits applied to reduce the company's income tax expense. It serves as a measure of the financial benefit derived from qualifying R&D expenditures under applicable tax laws. Investors monitor this to understand how much government policy supports the company's clinical or product development costs.
Ask your AI about Bicara Therapeutics's effective income tax rate reconciliation, tax credit, research, amount.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude